Status:
COMPLETED
Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)
Lead Sponsor:
Pfizer
Conditions:
Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
This study will examine the efficacy and safety of pegaptanib sodium in Japanese patients with wet-type AMD, in order to establish that there is no large difference in the efficacy and the safety of t...
Eligibility Criteria
Inclusion
- Wet AMD, Visual Acuity from 20/320 to 20/40
Exclusion
- Diabetic retinopathy, laser coagulation history
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00150202
Start Date
July 1 2004
End Date
October 1 2006
Last Update
May 7 2007
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Nagoya, Aichi-ken, Japan, 466-8560
2
Pfizer Investigational Site
Urayasu-shi, Chiba, Japan, 279-0021
3
Pfizer Investigational Site
Tokyo, Chiyoda-ku, Japan
4
Pfizer Investigational Site
Fukuoka, Fukuoka, Japan, 812-8582